Immunotherapy with mycobacterium vaccae in the treatment of tuberculosis

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 1701-1719

  Stanford, John ^a   Stanford, Cynthia ^a   Grange, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Immunopathology; Immunotherapy; Leprosy; Mycobacterium vaccae; Review; Tuberculosis

Indexed keywords

ETHAMBUTOL; INTERLEUKIN 2; ISONIAZID; MYCOBACTERIUM VACCINE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TETANUS TOXOID;

ASTHMA; BACTERIOLOGY; BODY WEIGHT; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FATIGUE; FLU LIKE SYNDROME; GEOGRAPHY; GUINEA PIG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INJECTION SITE; LEPROSY; LUNG TUBERCULOSIS; META ANALYSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM VACCAE; NONHUMAN; PSORIASIS; RANDOMIZATION; REVIEW; SEROLOGY; SHORT COURSE THERAPY; SIDE EFFECT; SKIN TEST; SPUTUM; TH1 CELL; TH2 CELL; TREATMENT FAILURE; WOUND HEALING; ACTIVE IMMUNIZATION; ANIMAL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; MYCOBACTERIUM; TUBERCULOSIS;

BACILLI; CAVIA PORCELLUS; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM VACCAE; SUS SCROFA;

ANIMALS; CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ACTIVE; LEPROSY; MYCOBACTERIUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 2442651874     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1292     Document Type: Review

References (91)

1. World Health Organization/International Union Against Tuberculosis and Lung Disease: Anti-tuberculosis drug resistance in the world. Report no. 2. Geneva: World Health Organization. (2000)
2. G Shaw: The doctors dilemma. Penguin Books, London (1957)
3. Koch R: An address on bacteriological research delivered before the International Medical Congress, held in Berlin, August 1890. Br Med J 2, 380-383 (1890)
4. Koch R: A further communication on a remedy for tuberculosis. Br Med J 1, 125-127 (1891)
5. Anonymous: Professor Koch's remedy for tuberculosis; Austria. Br Med J 2, 1480 (1890)
6. Spahlinger contra tuberculosis. 1908-1934. Eds: MacAssey L, Saleeby CW, John Bale, Sons and Danielsson, London (1934)
7. Orme I. M: The latent tubercle bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis 5, 589-593 (2001)
8. Friedmann F.F: Der Schildkröten-tuberkelbacillus, seine Züchtung, Biologie und Pathogenität. Zbl Bakt Orig I 34, 657-658 (1903)
9. P Werner. Der Heiler. Koehler und Amelang Verlag, München (2002)
10. Fowler W.C: A preliminary report on the treatment of tuberculosis with turtle vaccine. Tubercle 12, 12-15 (1930)
11. Bönicke R & S.E. Juhasz: Beschreibung der neuen Species Mycobacterium vaccae n.sp. Zbl Bakt Abt I, Orig A 192, 133-135 (1964)
12. Brown J. A. K, M. M. Stone & I. Sutherland: BCG vaccination of children against leprosy in Uganda. First results. Br Med J 1, 7-14 (1966)
13. Stanford J. L & R. C. Paul: A preliminary report on some studies of environmental mycobacteria. Ann Soc Belg Med Trop 53, 389-393 (1973)
14. Stanford J. L, M. J. Shield & G. A. W. Rook: How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 62, 55-62 (1981)
15. Stanford J. L, C. A. Stanford, K. Ghazi Saidi, Y. Dowlati, F. Weiss, Y. Farshchi, F. Madlener & R. J. W. Rees: Vaccination and skin test studies on the children of leprosy patients. Int J Lepr 57, 38-44 (1989)
16. Ganapati R. P, C. R. Revankar, D. N. P. Lockwood, R. Wilson, J. Price, P. M. Nye, P. Ashton, L. Ashton, R. Holmes, C. Bennett, J. L. Stanford & R. J. W. Rees: A pilot study of three potential vaccines for leprosy in Bombay. Int J Lepr 57, 33-37 (1989)
17. Ramu G, J. Grange & J. Stanford: Evaluation of adjunct immunotherapy with killed Mycobacterium vaccae in the treatment of multibacillary leprosy and erythema nodosum leprosum. In: Clinical Mycobacteriology. Ed: Casal M, Prous Science, Barcelona and Philadelphia (1998)
18. Rook G. A. & R. Hernandez-Pando: Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Novartis Found Symp 217, 73-87 (1998)
19. Yong A. J, J. M. Grange, R. D. Tee, J. S. Beck, G. H. Bothamley, D. M. Kemeny & T. Kardjito: Total and anti-mycobacterial IgE levels in serum from patients with tuberculosis and leprosy. Tubercle 70, 273-279 (1989)
20. Hernandez-Pando R, L. Pavon, E. H. Orozco, J. Range & G. A. Rook: Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice. Immunology 100, 391-398 (2000)
21. Wangoo A, T. Sparer, I. N. Brown, V. A. Snewin, R. Janssen, J. Thole, H. T. Cook, R. J. Shaw & D. B. Young: Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166, 3432-3439 (2001)
22. Rook G. A. W & J. L. Stanford: The relevance to protection of three forms of delayed skin test response evoked by M. leprae and other mycobacteria in mice: correlation with the classical work in the guinea pig. Parasite Immunol, 1, 111-123 (1979)
23. Stanford J. L, G. Cordess, G. A. W. Rook, S. Barnass & S. Lucas: Immunotherapy of tuberculosis in mice and guinea pigs. Proceedings of the International Tuberculosis Congress, Singapore 1986, Bull Int Union Tuberc 62, 10 (1987)
24. Filley E. A, H. A. Bull, H.A., P. M. Dowd & G. A. Rook: The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Immunology 77, 505-509 (1992)
25. Marshall B. G, M. A. Chambers, A. Wangoo, R. J. Shaw & D.B. Young: Production of tumor necrosis factor and nitric oxide by macrophages infected with live and dead mycobacteria and their suppression by an interleukin-10- secreting recombinant. Infect Immun 65, 1931-1935 (1997)
26. Wang C. C & G. A. Rook: Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 93, 307-13 (1998)
27. Hopfenspirger M. T, S. K. Parr, R. J. Hopp, R. G. Townley & D. K. Agrawal: Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma. Int J Immunopharmacol 1, 1743-1751 (2001)
28. Zuany-Amorim C, C. Manlius, A. Trifilieff, L. R. Brunet, G. Rook, G. Bowen, G. Pay & C. Walker: Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 169, 1492-1499 (2002)
29. Zuany-Amorim C, E. Sawicka, C. Manlius, A. Le Moine, L. R. Brunet, D. M. Kemeny, G. Bowen, G. Rook & C. Walker: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 8, 625-629 (2002)
30. Dhillon J & D. A. Mitchison: Effect of vaccines in a murine model of dormant tuberculosis. Tuber Lung Dis 75, 61-64 (1994)
31. Converse P. J, A. M. Dannenberg Jr, T. Shigenaga, D. N. McMurray, S. W. Phalen, J.L Stanford, G. A. Rook, T. Koru-Sengul, H. Abbey, J. E. Estep & M. L. Pitt: Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy. Clin Diagn Lab Immunol 5, 871-881 (1998)
32. Beck J.S, S.M. Morley, J.H. Gibbs, R.C. Potts, M.I. Ilias, T. Kardjito, J.M. Grange, J.L. Stanford & R.A. Brown: The cellular responses of tuberculosis and leprosy patients and of healthy controls in skin tests to new tuberculin and leprosin. Clin Exp Immunol 64, 484-494 (1986)
33. Potts R.C, J.S. Beck, J.H. Gibbs, J.M. Grange, T. Kardjito & J.L. Stanford: Measurements of blood flow and histometry of the cellular infiltrate in tuberculin skin test responses of the typical Koch-type and the non-turgid (Listeria-type) in pulmonary tuberculosis patients and apparently healthy controls. Int J Exp Pathol 73, 565-572 (1992)
34. Bothamley G.H & J.M. Grange: The Koch phenomenon and delayed hypersensitivity 1891-1991. Tubercle 72, 7-12 (1991)
35. Stanford J: Immunotherapy for mycobacterial disease. In: The Biology of the Mycobacteria Vol.3. Eds: Ratledge C, Stanford J, Grange J, Academic Press, London (1989)
36. Rook G. A. W, G. M. Bahr & J. L. Stanford: The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 62, 63-68 (1981)
37. Shield M. J, J. L. Stanford, R. C. Paul & J. W. Carswell: Multiple skin-testing of tuberculosis patients with a range of new tuberculins, and a comparison with leprosy and Mycobacterium ulcerans infection. J Hygiene (Lond) 78, 331-348 (1977)
38. Ewer K, J, Decks, L. Alvarez, G. Bryant, S. Waller, P. Andersen P, P. Monk & A. Lalvani: Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium Tuberculosis infection in a school tuberculosis outbreak. Lancet 361, 1168-1173 (2003)
39. Stanford J. L & E. Lema: The use of a sonicate preparation of Mycobacterium tuberculosis (new tuberculin) in the assessment of BCG vaccination. Tubercle 64, 275-282 (1983)
40. Stanford J. L, C. A. Stanford, G. A. W. Rook & J. M. Grange: Immunotherapy for tuberculosis. Investigative and practical aspects. Clinical Immunother 1, 430-440 (1994)
41. Stanford J. L, G. A. Rook, G. M. Bahr, Y. Dowlati, R. Ganapati, K. Ghazi Saidi, S. Lucas, G. Ramu, P. Torres, L. Ho Minh & N. Anstey: Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 8, 525-530 (1990)
42. Mackaness G. B: The immunology of antituberculous immunity. Am Rev Respir Dis 97, 337-344 (1967)
43. Lefford M. J: Delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 111, 243-246 (1975)
44. Grange J. M, J. S. Beck, E. I. Harper, T. Kardjito & J. L. Stanford: The effect of occupational exposure to patients with tuberculosis on dermal reactivity to four new tuberculins among healthy Indonesian adults. Tubercle 67, 109-118 (1986)
45. Kardjito T, J. S. Beck, J. M. Grange & J. L. Stanford: A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Eur J Respir Dis 69, 142-145 (1986)
46. Stanford J. L & J. M. Grange: The meaning and structure of species as applied to mycobacteria. Tubercle 55, 143-152 (1974)
47. Stanford J. L, P. M. Nye, G. A. W. Rook, N. Samuel & A. Fairbank: A preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to groups of shared or species antigens of mycobacteria. Lepr Rev 52, 321-327 (1981)
48. Nye P. M, J. E. Price, C. R. Revankar, G. A. W. Rook & J. L. Stanford: The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Lepr Rev 54, 9-18 (1983)
49. Morton A, P. M. Nye, G. A. W. Rook, N. Samuel & J. L. Stanford: A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Lepr Rev 55, 273-281 (1984)
50. Nye P. M, J. L. Stanford, G. A. W. Rook, P. Lawton, M. MacGregor, C. Reily, D. Humber, P. Orege, C. R. Revankar, J. Terencio de las Aguas & P. Torres: Suppressor determinants of mycobacteria and their potential relevance to leprosy. Lepr Rev 57, 147-157 (1986)
51. Godal T, B. Myrvang, J. L. Stanford & D. Samuel: Recent advances in the immunology of leprosy with special reference to new approaches in immunoprophylaxis. Bull Inst Pasteur 72, 273-310 (1974)
52. Draper P. & R.J.W. Rees: Report of the second IMMLEP task force meeting 1-5 December 1975. Protocol No. 2/75. Proposed system for preparing purified suspensions of M. leprae from tissues of infected armadillos. Lepr Rev 47, 320-323 (1976)
53. Stanford J. L, J. Terencio de las Aguas, P. Torres, B. O. Gervasioni & R. Ravioli: Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Cooperation Papers 7, Published by Organizzazione per la Cooperazione Sanitaria, Bologna, Italy: Proceedings of the Fourth European Leprosy Symposium 201-206 (1987)
54. Torres P, J. Gozalbez, J. Terencio de las Aguas & J. L. Stanford: A potential immunotherapeutic agent for leprosy tested in healthy volunteers. Health Cooperation Papers 7, Published by Organizzazione per la Cooperazione Sanitaria, Bologna, Italy: Proceedings of the Fourth European Leprosy Symposium 195-199 (1987)
55. Pozniak A, J. L. Stanford, N. McI. Johnson & G. A. W. Rook: Preliminary studies of immunotherapy of tuberculosis in man. Proceedings of the International Tuberculosis Congress, Singapore 1986. Bull Int Union Tuberculosis 62, 39-40 (1987)
56. Bahr G. M, J. L. Stanford, T. D. Chugh, M. A. Shaaban, M. Gabriel, B. Al Shimali, Z. Siddiqui, F. Ghardani, G. A. W. Rook, A. Shahin & K. Behbehani: An investigation of patients with pulmonary tuberculosis in Kuwait in preparation for studies of immunotherapy with Mycobacterium vaccae. Tubercle 71, 77-86 (1990)
57. Stanford J. L, G. M. Bahr, G. A. W. Rook, M. A. Shaaban, T. D. Chugh, M. Gabriel, B. Al Shimali, Z. Siddiqui, F. Ghardani, A. Shahin & K. Behbehani: Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 71, 87-93 (1990)
58. Bahr G. M, M. A. Shaaban, M. Gabriel, B. Al Shimali, Z. Siddiqui, T. D. Chugh, F. M. Denath, A. Shahin, K. Behbehanim, L. Chedid, G. A. W. Rook & J. L. Stanford: Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 71, 259-266 (1990)
59. Damais C, G. Riveau, M. Parant, J. Gerota & L. Chedid: Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol 4, 451-462 (1982)
60. Rook G. A, P. Onyebujoh, E. Wilkins, L. Ho Minh, R. al Attiyah, G. M. Bahr, T. Corrah, H. Hernandez & J. L. Stanford: A longitudinal study of per cent agalactosyl IgG in tuberculosis patients receiving chemotherapy, with or without immunotherapy. Immunology 81, 149-154 (1994)
61. Mayo R. E. & J. L. Stanford: Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans R Soc Trop Med Hyg 94, 563-568 (2000)
62. Foster S: Supply and use of essential drugs in Sub-Saharan Africa: Some issues and possible solutions. Soc Sci Med 32, 1201-1218 (1991)
63. McIlleron H, P. Wash, A. Burger, P. Folb & P. Smith: Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 6, 356-361 (2002)
64. Zwarenstein M, J. H. Schoeman, C. Vundule, C. J. Lombard & M. Tatley: Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 352, 1340-1343 (1998)
65. Onyebujoh P. C, T. Abdulmumini, S. Robinson, G. A. W. Rook & J. L. Stanford: Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 89, 199-207 (1995)
66. Stanford J. L, P. C. Onyebujoh, G. A. W. Rook, J. M. Grange & A. Pozniak: Old plague, new plague and a treatment for both? (letter) AIDS 7, 1275-1277 (1993)
67. Corlan E, C. Marica, C. Macavei, J. L. Stanford & C. A. Stanford: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respir Med 91, 13-19 (1997)
68. Corlan E, C. Marica, C. Macavei, J. L. Stanford & C. A. Stanford: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 91, 21 -29 (1997)
69. Dlugovitzky D, O. Bottasso, J. C. Dominino, E. Valentini, R. Hartopp, M. Singh, C. Stanford & J. L. Stanford: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med 93, 557-562 (1999)
70. Stanford J. L, C. A. Stanford, A. Etemadi, R. Farid, C. Marica & E. Corlan: Immunotherapy for multi-drug resistant tuberculosis. J Am Med Assoc, Southeast Asia 10, Supplement No.3, 42-46 (1994)
71. Wang W, G. Jin, Y. Ye, X. Xia, A. Wang, Y. Zhuang, G. Li, H. Sun, Z. Wang, M. Lin, H. Chen, J. Li, Z. Dan & X. Zhang: A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis (in Chinese) Zhonghua Jie He He Hu Xi Za Zhi 22, 108-110 (1999)
72. Luo Y: National Cooperation Group On Clinical Study Of Mycobacterium Vaccae Vaccine. The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 24, 43-47 (2001)
73. Durban Immunotherapy trial Group: Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 354, 116-119 (1999)
74. Johnson J. L, R. M. Kamya, A. Okwera, A.M. Loughlin, S. Nyole, D. L. Horn, R. S. Wallis, C. S. Hirsch, K. Wolski, J. Foulds, R. D. Mugerwa & J. J. Ellner: Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 181, 1304-1312 (2000)
75. Mwinga A, A. Nunn, B. Ngwira, C. Chintu, D. Warndorff, P. Fine, J. Darbyshire & A. Zumla: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 360, 1050-1055 (2002)
76. Stanford J. L, C. A. Stanford, J. M. Grange, L. Nguyen Ngoc & A. Etemadi: Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for multi-drug-resistant pulmonary tuberculosis? Respir Med 95, 444-447 (2001)
77. Etemadi A, R. Farid & J. L. Stanford: Immunotherapy for drug-resistant tuberculosis. Lancet 340, 360-361 (1992)
78. Farid R, A. Etemadi, M. Mehvar, J. L. Stanford, Y. Dowlati & A. A. Velayati: Mycobacterium vaccae immunotherapy in the treatment of multi-drug-resistant tuberculosis: a preliminary report. Iran J Med Sci 19, 37-39 (1994)
79. Luo Y, S. Lu & S. Guo: Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 23, 85-88 (2000)
80. Johnson D, R. D. Waddell, S. I. Pelton, A. S. Jaeger, J. F. Modlin, R. Yogev, P. Morin P, R. D. Arbeit & C. F. von Reyn: Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Vaccine 17, 2583-2587 (1999)
81. Waddell R. D, C. Chintu, A. D. Lein, A. Zumla, M. R. Karagas, K. S. Baboo, J. D. Habbema, A. N. Tosteson, P. Morin, S. Tvaroha, R. D. Arbeit, A. Mwinga & C. F. von Reyn: Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis Suppl 3, S309-S315 (2000)
82. Ramu G, G. D. Prema, S. Balakrishnan, N. P. Shanker Narayan & J. L. Stanford: A preliminary report on the immunotherapy of psoriasis. Ind Med Gaz 124, 381-382 (1990)
83. Lehrer A, A. Bressanelli, V. Wachsmann, Q. Bottasso, M. L. Bay, M. Singh, C. Stanford & J. L. Stanford: Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol, Med Microbiol 21, 71-77 (1998)
84. Balagon M. V, D. S. Walsh, P. L. Tan, R. V. Cellona, R. M. Abalos, E. V. Tan, T. T. Fajardo, J. D. Watson & G. P. Walsh: Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae. Int J Dermatol 39, 51-58 (2000)
85. Camporota L, A. Corkhill, H. Long, J. Lordan, L. Stanciu, N. Tuckwell, A. Cross, J. L. Stanford, G. A. Rook, S. T. Holgate & R. Djukanovic: The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 21, 287-93 (2003)
86. Stansby G, Y. C. Chan, C. S. Berwanger, S. Shurey, G. A. W. Rook & J. L. Stanford: Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 2002; 23: 23-28.
87. Abbot N. C, J. S. Beck, F. Feval, F. Weiss, M. H. Mobayen, K. Ghazi-Saidi, Y. Dowlati, A. A. Velayati & J. L. Stanford: Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 24, 202-208 (2002)
88. Hernandez-Pando R, L. Pavon, K. Arriaga, H. Orozco, V. Madrid-Marina & G. A. Rook: Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 65, 3317-3327 (1997)
89. de Bruyn G & P. Garner: Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev CD001166 (2003)
90. Stanford J. L, C. A. Stanford, B. Baban & J. M. Grange: Therapeutic vaccination for cancer: the potential value of mycobacterial products. Int J Pharm Med 12, 191-195 (1999)
91. Stanford J. L & J. M. Grange: New concepts for the control of tuberculosis in the twenty first century. J R Coll Physicians Lond 27, 218-223 (1993)